Clionix and Q Bio Med Sign License Agreement for the Distribution and Sales of Strontium89 in Europe and Middle East

Clionix will be the exclusive distributor of Strontium89 in Turkey, Saudi Arabia,
Azerbaijan, Bulgaria, Romania, Egypt, Kuwait, & Pakistan.

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech
company, announced today that it has recently entered into an exclusive license agreement
with Clionix, a reputable distributor in Europe and the Middle East. Clionix is an authorized
distributor, contributor and reseller of several products in the life sciences domain including
nuclear medicine, oncology and molecular diagnostics. Under the terms of the agreement,
Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia,
Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.
Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment
of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.
Common primary tumors that metastasize to the bone include prostate, breast, and lung, as
well as others.
In the Strontium89 pivotal trial, as many as 79% of patients had pain relief with Strontium89,
and twice as many patients treated with Strontium89 had no pain for 3 months compared with
placebo. Further, new pain sites were less frequent in patients treated
with Strontium891,2

Over ten million people around the world suffer from pain associated with metastatic cancer
in the bone and may benefit from Strontium89. For nearly two years, there has been little to
no access to this vital therapy. Clionix and Q BioMed will work together to increase the
awareness of doctors and patients to the availability of Strontium89. Q BioMed is actively
pursuing full regulatory and marketing approval for Strontium89 in these markets as well as in
other markets worldwide.
Kristin Keller, Q BioMed Chief Commercial Officer, said, “We are very happy to collaborate
with Clionix and bring Strontium89, a viable treatment for patients suffering from painful
skeletal metastases caused by cancer to these markets. We are actively working to ensure
that Strontium89 is accessible to patients everywhere and to extend its relevance and use
thorough additional clinical study.”
Hasan Ozcan, Clionix General Manager said: “As we are focused in providing
radiopharmaceuticals in the region, we are happy to partner with Q BioMed and bring
Strontium89 to provide doctors and patient with this important and useful treatment option.”

For the full text :

About the Author

You may also like these